BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Chicago Capital, LLC 1,000$347,0000.02%
Crossmark Global Holdings, Inc. 2,058$714,0000.02%
Retirement Systems of Alabama 13,006$4,508,0000.02%
Manchester Capital Management LLC 310$107,0000.02%
VALLEY WEALTH MANAGERS, INC. 541$188,0000.02%
RAYMOND JAMES TRUST N.A. 1,474$511,0000.02%
Epoch Investment Partners, Inc. 8,683$3,010,0000.02%
ALLSTATE CORP 1,684$584,0000.02%
Laird Norton Wetherby Wealth Management, LLC 769$267,0000.02%
EATON VANCE MANAGEMENT 36,447$12,634,0000.02%
Symmetry Partners, LLC 790$274,0000.02%
BNP PARIBAS FINANCIAL MARKETS 30,868$10,700,084,0000.02%
EQUITABLE TRUST CO 650$225,0000.02%
DIMENSIONAL FUND ADVISORS LP 140,002$48,528,0000.02%
ROYAL BANK OF CANADA 165,524$57,375,0000.02%
CANADA LIFE ASSURANCE Co 18,918$6,562,0000.02%
OREGON PUBLIC EMPLOYEES RETIREMENT FUND 3,020$1,047,0000.02%
Rockefeller Capital Management L.P. 8,831$3,061,0000.02%
Norinchukin Bank, The 2,347$814,0000.02%
DekaBank Deutsche Girozentrale 15,381$5,177,0000.02%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.